Skip to main content
SpringerLink
Log in

Biologics (Vaccines, Antibodies, Enzymes) to Treat Drug Addictions

  • Reference work entry
  • First Online:
Textbook of Addiction Treatment: International Perspectives

Abstract

A novel approach for the treatment of substance use disorders (SUDs) is the use of biologics. Biologics include immunotherapies, such as vaccines or antibodies, as well as enzymes. These are usually large and complex molecules that do not cross the blood-brain barrier and do not have effects in the central nervous system (CNS). Biologics are investigated for the treatment of SUDs because they prevent the access of the drug of abuse to the brain and, thus, prevent their effect of brain reward systems. It is expected that over a period of treatment with biologics, they will help to produce an extinction of the brain mechanisms of drug dependence. SUDs are complex medical conditions that require multiple therapeutic approaches and the treatment with biologics may offer a new way to treat these disorders without directly affecting the brain. The purpose of this chapter is to provide a general overview of the current status of research with vaccines, antibodies, and enzymes for the treatment of SUDs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 339.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anton B, Leff P (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24:3232–3240

    Article  CAS  PubMed  Google Scholar 

  • Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez JA et al (2009) Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccine 5:214–229

    Article  CAS  Google Scholar 

  • Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252:708–710

    Article  CAS  PubMed  Google Scholar 

  • Brimijoin S, Gao Y, Anker JJ, Gliddon LA, LaFleur D, Shah R et al (2008) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33:2715–2725

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y et al (2009) The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 52:7301–7309

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Carroll ME, Gao Y, Brimijoin S, Anker JJ (2011) Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl) 213:817–829

    Article  CAS  Google Scholar 

  • Celtic Pharma (2012a) Study of TA-NIC to assess the efficacy and safety of the vaccine as an aid to smoking cessation. http://clinicaltrials.gov/ct2/show/NCT00633321

  • Celtic Pharma (2012b) TA-NIC nicotine dependence. http://www.celticpharma.com/theportfolio/ta-nic.html

  • Collins GT1, Brim RL, Noon KR, Narasimhan D, Lukacs NW, Sunahara RK, Woods JH, Ko MC (2012) Repeated administration of a mutant cocaine esterase: effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys. J Pharmacol Exp Ther 342(1):205–213

    Google Scholar 

  • Cytos Biotechnology (2012a) New clinical study started with the nicotine vaccine NIC002. http://www.cytos.com/userfiles/file/Cytos_Press_E_101105.pdf

  • Cytos Biotechnology (2012b) NIC002 (formerly CYT002-NicQb): a novel vaccine for nicotine addiction. http://www.cytos.com/doc/NIC002_Nicaddiction_Facts_August07.pdf

  • de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Malmerfelt A, Johansson AM et al (2002) Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 69:247–253

    Article  PubMed  Google Scholar 

  • de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Baraznenok I, Malmerfelt A et al (2010) Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 28:2161–2168

    Article  PubMed  Google Scholar 

  • Duryee MJ, Bevins RA, Reichel CM, Murray JE, Dong Y, Thiele GM et al (2009) Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 27:2981–2988

    Article  CAS  PubMed  Google Scholar 

  • Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ et al (1996) Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2:1129–1132

    Article  CAS  PubMed  Google Scholar 

  • Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S (2010) The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact 187:421–424

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gentry WB, Ruedi-Bettschen D, Owens SM (2009) Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccine 5:206–213

    Article  CAS  Google Scholar 

  • Gentry WB, Ruedi-Bettschen D, Owens SM (2010) Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin Pharmacol Ther 88:390–393

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Godin CS, Shemesh-Davish L, Sklair-Tavron L, Rosenstock M (2012) TV-1380 (Albumin-Fused Mutated Bche) attenuates the cardiovascular and respiratory effects induced by cocaine in cynomolgus monkeys. http://www.avanzalaboratories.com/abstract/Teva%20Poster%20SOT%202010.pdf

  • Gorelick DA (2012) Pharmacokinetic strategies for treatment of drug overdose and addiction. Futur Med Chem 4:227–243

    Article  CAS  Google Scholar 

  • Gu F, Langer R, Farokhzad OC (2009) Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol 544:589–598

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA et al (2011) Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89:392–399

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hicks MJ, De BP, Rosenberg JB, Davidson JT, Moreno AY, Janda KD et al (2011) Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 19:612–619

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kantak KM (2003) Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 4:213–218

    Article  CAS  PubMed  Google Scholar 

  • Kinsey BM, Jackson DC, Orson FM (2009) Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 87:309–314

    Article  CAS  PubMed  Google Scholar 

  • Kinsey BM, Kosten TR, Orson FM (2010) Anti-cocaine vaccine development. Expert Rev Vaccines 9:1109–1114

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J et al (2002) Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20:1196–1204

    Article  CAS  PubMed  Google Scholar 

  • Li QQ, Luo YX, Sun CY, Xue YX, Zhu WL, Shi HS et al (2011) A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 119:1271–1281

    Article  CAS  PubMed  Google Scholar 

  • Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58:158–164

    Article  CAS  PubMed  Google Scholar 

  • McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M et al (2013) Enhancing immunogenicity of a 3′aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates

    Google Scholar 

  • McGee D, Godin S (2013) RBP-8000: A Dose Escalation Cocaine Interaction study in Male Sprague Dawley Rats. Abstract. http://www.smithersavanza.com/documents/Reckitt-Poster-Abstract-31-Oct-2013.pdf

  • Montoya ID, Vocci F (2008) Novel medications to treat addictive disorders. Curr Psychiatry Rep 10:392–398

    Article  PubMed Central  PubMed  Google Scholar 

  • Moreno AY, Mayorov AV, Janda KD (2011) Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 133:6587–6595

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nabi Pharmaceuticals (2012) NicVAX® (Nicotine Conjugate Vaccine). http://www.nabi.com/pipeline/pipeline.php?id=3

  • Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR (2008) Substance abuse vaccines. Ann N Y Acad Sci 1141:257–269

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Peterson EC, Owens SM (2009) Designing immunotherapies to thwart drug abuse. Mol Interv 9:119–124

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pfizer at USB Global Life Sciences Conference – Edited Transcript. Thomson Reuters Streetevents. (http://www.pfizer.com/files/investors/presentations/public_ubs_transcript_092012.pdf). Accessed Sept 2012

  • Pravetoni M, Le NM, Harmon TM, Tucker AM, Portoghese PS, Pentel PR (2012) An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther 341:225–232

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pravetoni M, Le NM, Tucker AM, Harmon TM, Hawley TM, Portoghese PS et al (2013) Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 56:915–923

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Selecta Biosciences (2012) Selecta biosciences initiates phase 1 clinical study of SEL-068, a first-in-class synthetic nicotine vaccine for smoking cessation and relapse prevention http://www.selectabio.com/news/recent-news/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm

  • Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G et al (2011) A vaccine strategy that induces protective immunity against heroin. J Med Chem 54:5195–5204

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tonstad S, Heggen E, Giljam H, Lagerbäck PÃ…, Tønnesen P, Wikingsson LD, Lindblom N, de Villiers S, Svensson TH, Fagerstr­m KO (2013) Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 15(9):1492–1501

    Google Scholar 

  • Treweek JB, Roberts AJ, Janda KD (2011) Immunopharmacotherapeutic manifolds and modulation of cocaine overdose. Pharmacol Biochem Behav 98:474–484

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • U.S. Food and Drug Administration (1999) Regulation of biological products. 42USC262 [On-line]. http://www.fda.gov/RegulatoryInformation/Legislation/ucm149278.htm

  • Unknown (2012) Swedish scientists working on Niccine, a vaccine to fight against http://healthvox.info/?p=33

  • Zheng F, Zhan CG (2009) Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications. Futur Med Chem 1:515–528

    Article  CAS  Google Scholar 

  • Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D et al (2008) Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130:12148–12155

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse (NIDA), 6001 Executive Blvd, Bethesda, MD, 20892, USA

    Ivan D. Montoya

Authors
  1. Ivan D. Montoya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan D. Montoya .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Alberta Gambling Research Institute University of Calgary, Calgary, Alberta, Canada

    Nady el-Guebaly

  2. Faculty of Brain Sciences UCL Division of Psychiatry, University College London, London, United Kingdom

    Giuseppe Carrà

  3. Division of Alcoholism & Drug Abuse, New York University School of Medicine, New York, New York, USA

    Marc Galanter

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this entry

Cite this entry

Montoya, I.D. (2015). Biologics (Vaccines, Antibodies, Enzymes) to Treat Drug Addictions. In: el-Guebaly, N., Carrà, G., Galanter, M. (eds) Textbook of Addiction Treatment: International Perspectives. Springer, Milano. https://doi.org/10.1007/978-88-470-5322-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5322-9_31

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5321-2

  • Online ISBN: 978-88-470-5322-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation